Epcoritamab demonstrated an improvement in progression-free survival in certain patients with relapsed or refractory (R/R) ...

Danish drugmaker Genmab and its U.S. partner AbbVie said on Friday that their drug for a type of blood cancer failed to ...

Based on the topline results from the EPCORE ® DLBCL-1 trial, Genmab will engage global regulatory authorities to discuss ...

Genmab (GMAB) stock slips as trial data for the company's lymphoma therapy Epkinly (epcoritamab) marketed with AbbVie (ABBV) falls short of expectations. Read more here.

Cervical lymphadenopathy presents a shared anatomic challenge for clinicians, yet it serves as the divergent starting point ...

Artiva Biotherapeutics is developing NK cell immunotherapy for autoimmune disease. Early trial data in B-cell lymphoma ...

Eleven patients with refractory autoimmune hemolytic anemia (AIHA) were all brought into drug-free remission with CAR T-cell ...

The combination of axi-cel and rituximab showed high efficacy in refractory LBCL, with a 73% complete response rate and 88% overall response rate. Safety was favorable, with no new signals; 96% ...

The first leukaemia patient to receive a breakthrough treatment since it was made available on the NHS has said it was ...

Preliminary total global full year 2025 revenue of approximately $616 millionPreliminary BRIUMVI U.S. fourth quarter and full year 2025 net ...

The CEO of ModeX Therapeutics discusses MDX2003, a groundbreaking tetraspecific therapy that promises enhanced efficacy and ...

It's true that vitamin C can give your immune system a boost, but when it comes to treating or preventing colds, things get a ...